ATE112633T1 - Verwendung von einem antikörperkonjugat zum nachweis von nekrotischem malignem gewebe und für die assoziierte therapie. - Google Patents

Verwendung von einem antikörperkonjugat zum nachweis von nekrotischem malignem gewebe und für die assoziierte therapie.

Info

Publication number
ATE112633T1
ATE112633T1 AT87310566T AT87310566T ATE112633T1 AT E112633 T1 ATE112633 T1 AT E112633T1 AT 87310566 T AT87310566 T AT 87310566T AT 87310566 T AT87310566 T AT 87310566T AT E112633 T1 ATE112633 T1 AT E112633T1
Authority
AT
Austria
Prior art keywords
antibody
therapy
mammal
disclosed
antineoplastic agent
Prior art date
Application number
AT87310566T
Other languages
English (en)
Inventor
Alan L Epstein
Clive R Taylor
Original Assignee
Cancer Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Biolog Inc filed Critical Cancer Biolog Inc
Application granted granted Critical
Publication of ATE112633T1 publication Critical patent/ATE112633T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT87310566T 1986-12-05 1987-12-01 Verwendung von einem antikörperkonjugat zum nachweis von nekrotischem malignem gewebe und für die assoziierte therapie. ATE112633T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/938,425 US4861581A (en) 1986-12-05 1986-12-05 Detection of necrotic malignant tissue and associated therapy

Publications (1)

Publication Number Publication Date
ATE112633T1 true ATE112633T1 (de) 1994-10-15

Family

ID=25471418

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87310566T ATE112633T1 (de) 1986-12-05 1987-12-01 Verwendung von einem antikörperkonjugat zum nachweis von nekrotischem malignem gewebe und für die assoziierte therapie.

Country Status (9)

Country Link
US (1) US4861581A (de)
EP (1) EP0270340B1 (de)
JP (1) JP2733658B2 (de)
AT (1) ATE112633T1 (de)
AU (1) AU603161B2 (de)
CA (1) CA1335720C (de)
DE (1) DE3750630T2 (de)
NZ (1) NZ222744A (de)
ZA (1) ZA879076B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2785025B2 (ja) * 1985-03-19 1998-08-13 ランデル・エル・ミルズ 診断と選択的組織壊死を与える装置
US4940670A (en) * 1986-01-24 1990-07-10 Rhodes Buck A Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use
US4950469A (en) * 1986-05-30 1990-08-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US5017648A (en) * 1986-05-30 1991-05-21 La Jolla Pharmaceutical Company D-GL conjugate therapy
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5304635A (en) * 1990-03-12 1994-04-19 University Of Southern California Antigen specifically expressed on the surface of B cells and Hodgkin's cells
WO1991013633A1 (en) * 1990-03-12 1991-09-19 Cancer Research Campaign Technology Limited Improvements relating to immunoradiotherapy
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US5155210A (en) * 1990-09-11 1992-10-13 Brunswick Corporation Methods of conjugating actinomycin d
US5401489A (en) * 1991-05-01 1995-03-28 University Of New Mexico Biomodulators as universal imaging agents
JPH06509102A (ja) * 1991-07-01 1994-10-13 マリンクロッド・メディカル・インコーポレイテッド 体内造影抗イディオタイプ抗体を用いた組織特異的造影剤
JP3190042B2 (ja) * 1991-10-31 2001-07-16 マトリテク インコーポレイテッド 核マトリックス蛋白液アッセー
EP0697891B1 (de) 1993-05-05 2000-03-29 Keith Rose Polyoximverbindungen und deren herstellung
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
US5535746A (en) * 1994-03-29 1996-07-16 Sterling Winthrop Inc. Prefilled syringe for use with power injector
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5565200A (en) * 1995-04-14 1996-10-15 University Of Southern California Pharmaceutical preparations derived from korean mistletoe
US6379714B1 (en) 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
US5547674A (en) * 1995-04-14 1996-08-20 University Of Southern California Pharmaceutical preparations derived from European mistletoe
US20050025740A1 (en) * 1996-01-05 2005-02-03 Keith Rose Polyoxime compounds and their preparation
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
US6080383A (en) * 1997-01-13 2000-06-27 Rose; Samuel Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
US6751290B2 (en) 1998-09-08 2004-06-15 Veritas Pharmaceuticals, Inc. Radiographic assessment of tissue after exposure to a compound
US6723746B2 (en) 1998-09-08 2004-04-20 Veritas Pharmaceuticals, Inc. Functional radiographic imaging methods and agents
US6226352B1 (en) * 1998-09-08 2001-05-01 Veritas Pharmaceuticals, Inc. System and method for radiographic imaging of tissue
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7256271B2 (en) 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US6510389B1 (en) 2000-02-25 2003-01-21 Schlumberger Technology Corporation Acoustic detection of stress-induced mechanical damage in a borehole wall
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7431923B2 (en) 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
US6930171B2 (en) * 2002-02-07 2005-08-16 Solbec Pharmaceuticals Limited Rhamnose binding protein
EP2283868B1 (de) 2002-07-15 2016-03-30 Board of Regents, The University of Texas System Peptide mit Bindung an Phosphatidylethanolamine und ihre Verwendung bei der Behandlung von Virusinfektionen und Krebs
US7175846B2 (en) * 2003-01-21 2007-02-13 Arius Research Inc. Cancerous disease modifying antibodies
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
CA2531878A1 (en) * 2003-05-09 2005-03-24 Curagen Corporation Therapeutic use of g53135-05(fgf-20) in radiation protection
DE602004015454D1 (de) 2003-06-25 2008-09-11 Peregrine Pharmaceuticals Inc Verfahren und vorrichtung zur kontinuierlichen radioaktiven markierung von proteinen im grossen massstab
US20050027106A1 (en) * 2003-07-28 2005-02-03 Young David S. F. Cancerous disease modifying antibodies
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US20050255041A1 (en) * 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2521973C (en) * 2004-09-29 2013-12-10 Tir Systems Ltd. System and method for controlling luminaires
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP1994146A4 (de) * 2006-02-24 2010-06-09 Hoffmann La Roche Krebserkrankung-modifizierender antikörper 141205-02
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CN101675158A (zh) * 2006-02-24 2010-03-17 阿里乌斯研究公司 癌性疾病调节抗体
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
CA2668484A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies 180706-02
AU2007321664A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
BRPI0718609A8 (pt) * 2006-11-13 2015-09-29 Arius Res Inc Anticorpos modificadores de doença cancerosa.
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
EP2126055A4 (de) * 2007-03-26 2011-11-23 Hoffmann La Roche Mittels hybridoma-zelllinie ar51a630.3 hergestellter tumormodifizierender antikörper 010207-01
AU2008247285A1 (en) * 2007-05-07 2008-11-13 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
WO2009124381A1 (en) * 2008-04-10 2009-10-15 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
CA2724782A1 (en) * 2008-05-19 2009-11-26 Takeda Pharmaceutical Company Limited An anti-cancer cytotoxic monoclonal antibody
CA2731129A1 (en) * 2008-07-17 2010-01-21 Helen P. Findlay Cancerous disease modifying antibodies
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
JP2011206049A (ja) 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
JP6791763B2 (ja) 2014-06-26 2020-11-25 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 疾患および障害の処置においてレナラーゼを制御する組成物および方法
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
NZ748983A (en) 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP2020515637A (ja) 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
AU2019362029B2 (en) 2018-10-19 2025-06-12 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
CN110904059B (zh) * 2019-11-18 2021-03-23 华中农业大学 花青素合成酶抗原表位肽及其抗体与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157373A (en) * 1980-01-04 1983-11-22 Harris Busch Detection of human cancer cells with antibodies to human cancer nucleolar antigen(s)
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4499183A (en) * 1982-12-21 1985-02-12 Ortho Diagnostic Systems Inc. Detecting intracellular antigens in swelled and fixed cells with labeled antibody
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells

Also Published As

Publication number Publication date
EP0270340A3 (en) 1990-01-17
AU603161B2 (en) 1990-11-08
CA1335720C (en) 1995-05-30
JPS63218628A (ja) 1988-09-12
AU8204787A (en) 1988-06-09
JP2733658B2 (ja) 1998-03-30
DE3750630T2 (de) 1995-05-04
ZA879076B (en) 1988-05-30
EP0270340B1 (de) 1994-10-05
NZ222744A (en) 1990-01-29
DE3750630D1 (de) 1994-11-10
EP0270340A2 (de) 1988-06-08
US4861581A (en) 1989-08-29

Similar Documents

Publication Publication Date Title
DE3750630D1 (de) Verwendung von einem Antikörperkonjugat zum Nachweis von nekrotischem malignem Gewebe und für die assoziierte Therapie.
Ceriani et al. Circulating human mammary epithelial antigens in breast cancer.
ES8505482A1 (es) Un procedimiento para preparar un producto que contiene un anticuerpo monoclonal y un radionuclido metalico
DE3887675D1 (de) Antikörper.
NO863974D0 (no) Monoklonale antihuman brystkreftantistoffer.
DE3685625D1 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
GB1498081A (en) Covalently bound biological substances to plastic materials and use in radioassay
DE69433590D1 (de) Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren
BG42837A3 (bg) Метод за получаване на имуноглобулинови производни на винка алкалоиди
Mahaley Jr et al. The Localization of Radioantibodies in Human Brain Tumors: II. Radioautography
FR2297034B1 (de)
Monaco et al. Casein production by human breast cancer
ES2033823T3 (es) Ensayo en cuanto a cancer de mama humano.
Talerman et al. Demonstration of calcitonin and carcinoembryonic antigen (CEA) in medullary carcinoma of the thyroid (MCT) by immunoperoxidase technique
Sakakibara et al. Localization of type III procollagen aminopeptide antigenicity in hepatocytes from cirrhotic human liver
ES2033834T3 (es) Un metodo para determinar alteraciones de la gestion.
EP0143367A3 (de) Verfahren zur Herstellung monoklonaler Antikörper für Krebsdiagnose und Therapie
DE3689299D1 (de) Verwendung von amphipatischen Molekülen zur Radiodarstellung und Therapie mittels monoklonaler oder polyklonaler Antikörperkonjugate.
Eber et al. Immunoradiometric assay for human thyroglobulin and variations in thyroid pathology
Tapp et al. Radioimmunoassay for melatonin
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
RU1827022C (ru) Способ активации цитотоксических клеток
Page et al. Drug targeting with monoclonal antibodies
Piñeiro et al. An immunoenzymatic method for improving the sensitivity of antigen measurement by electroimmunodiffusion techniques. Application to the quantification of human alpha-fetoprotein
RU96112578A (ru) Способ выявления дифтерийного токсина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties